Pharmacophore modeling for hERG channel facilitation

Biochemical and Biophysical Research Communications

Volumn 418, Issue 1, 2012, Pages 161-166

  Yamakawa, Yuko ^a   Furutani, Kazuharu ^a   Inanobe, Atsushi ^a   Ohno, Yuko ^a   Kurachi, Yoshihisa ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Facilitation; HERG channel; Pharmacology; Pharmacophore model

Indexed keywords

ATENOLOL; CHLORPHENIRAMINE; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; METOPROLOL; NORTRIPTYLINE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; PROMETHAZINE; PROPRANOLOL; SOTALOL; TERFENADINE; VERAPAMIL;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION COEFFICIENT; FACILITATION; HEART MUSCLE POTENTIAL; HYDROPHOBICITY; IONIZATION; NONBIOLOGICAL MODEL; NONHUMAN; OOCYTE; PHARMACOPHORE; POTASSIUM CURRENT; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; XENOPUS LAEVIS;

ANIMALS; ATENOLOL; CHLORPHENIRAMINE; ETHER-A-GO-GO POTASSIUM CHANNELS; FLUOXETINE; HALOPERIDOL; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; IMIPRAMINE; METOPROLOL; NORTRIPTYLINE; POTASSIUM CHANNEL BLOCKERS; PROMETHAZINE; PROPRANOLOL; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SOTALOL; TERFENADINE; VERAPAMIL; XENOPUS LAEVIS;

EID: 84856484667     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.12.153     Document Type: Article

References (26)

1. Sanguinetti M.C., Jiang C., Curran M.E., et al. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995, 81:299-307.
2. Sanguinetti M.C., Tristani-Firouzi M. HERG potassium channels and cardiac arrhythmia. Nature 2006, 440:463-469.
3. Trudeau M.C., Warmke J.W., Ganetzky B., et al. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1995, 269:92-95.
4. Roden D.M. Acquired long QT syndromes and the risk of proarrhythmia. J. Cardiovasc. Electrophysiol. 2000, 11:938-940.
5. Redfern W.S., Carlsson L., Davis A.S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 2003, 58:32-45.
6. Carmeliet E. Use-dependent block and use-dependent unblock of the delayed rectifier K+ current by almokalant in rabbit ventricular myocytes. Circ. Res. 1993, 73:857-868.
7. Jiang M., Dun W., Fan J.S., et al. Use-dependent 'agonist' effect of azimilide on the HERG channel. J. Pharmacol. Exp. Ther. 1999, 291:1324-1336.
8. Hosaka Y., Iwata M., Kamiya N., et al. Mutational analysis of block and facilitation of HERG current by a class III anti-arrhythmic agent, nifekalant. Channels (Austin) 2007, 1:198-208.
9. Furutani K., Yamakawa Y., Inanobe A., et al. A mechanism underlying compound-induced voltage shift in the current activation of hERG by antiarrhythmic agents. Biochem. Biophys. Res. Commun. 2011, 415:141-146.
10. Kroemer R.T. Structure-based drug design: docking and scoring. Curr. Protein Pept. Sci. 2007, 8:312-328.
11. Reddy A.S., Pati S.P., Kumar P.P., et al. Virtual screening in drug discovery - a computational perspective. Curr. Protein Pept. Sci. 2007, 8:329-351.
12. Coi A., Massarelli I., Murgia L., et al. Prediction of hERG potassium channel affinity by the CODESSA approach. Bioorg. Med. Chem. 2006, 14:3153-3159.
13. Sanguinetti M.C., Mitcheson J.S. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol. Sci. 2005, 26:119-124.
14. Ekins S., Crumb W.J., Sarazan R.D., et al. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J. Pharmacol. Exp. Ther. 2002, 301:427-434.
15. Durdagi S., Duff H.J., Noskov S.Y. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain. J. Chem. Inf. Model 2011, 51:463-474.
16. Cavalli A., Poluzzi E., De Ponti F., et al. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. J. Med. Chem. 2002, 45:3844-3853.
17. Inanobe A., Kamiya N., Murakami S., et al. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current. J. Physiol. Sci. 2008, 58:459-470.
18. Fernandez D., Ghanta A., Kauffman G.W., et al. Physicochemical features of the HERG channel drug binding site. J. Biol. Chem. 2004, 279:10120-10127.
19. Aronov A.M. Predictive in silico modeling for hERG channel blockers. Drug Discov. Today 2005, 10:149-155.
20. Mitcheson J.S., Chen J., Lin M., et al. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. USA 2000, 97:12329-12333.
21. Patane S., Marte F., Di Bella G. QT interval prolongation and torsade de pointes. Int. J. Cardiol. 2009, 131:e51-e53.
22. D.W. Chong, S.J. Ankolekar, J. McDonald, Sotalol induced QT prolongation and torsades de pointes. BMJ Case Rep. (2009).
23. Michiels V., Miljoen H., Vrints C. Gastroenteritis with severe consequences: a case of sotalol-induced torsades de pointes. Acta Cardiol. 2009, 64:839-842.
24. Hanyok J.J. Clinical pharmacokinetics of sotalol. Am. J. Cardiol. 1993, 72:19A-26A.
25. de Abajo F.J., Rodriguez L.A. Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs. Br. J. Clin. Pharmacol. 1999, 47:307-313.
26. Hondeghem L.M., Dujardin K., Hoffmann P., et al. Drug-induced QTC prolongation dangerously underestimates proarrhythmic potential: lessons from terfenadine. J. Cardiovasc. Pharmacol. 2011, 57:589-597.